When excluding the three patients that also had tissue biopsies with a luminal breast cancer subtype and PD-L1 negative status median PFS in the first line treatment cohort was 4.63 months (SE = 2.28, 95%CI [.16; 9.10], Kaplan–Meier method) compared to 2.99 months (SE = 1.16, 95%CI [.71; 5.27], Kaplan–Meier method) in the second and beyond treatment line (p = .233). Here, CD274 is linked to breast carcinoma.